Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has issued an update.
GenFleet Therapeutics announced the dosing of the first patient in a Phase Ib/II study of GFH375, combined with cetuximab or chemotherapy, for advanced solid tumors, including first-line pancreatic ductal adenocarcinoma (PDAC). This trial, approved by China’s National Medical Products Administration, aims to evaluate the safety, efficacy, and pharmacokinetic profile of GFH375. The study marks a significant step in expanding GFH375’s clinical development from later-line to frontline settings, potentially enhancing its impact across major cancer types.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a biopharmaceutical company focused on the development of innovative cancer therapies. The company specializes in targeting the RAS/MAPK pathway-driven cancers with its primary product being GFH375, an oral KRAS G12D inhibitor.
Average Trading Volume: 3,338,692
See more data about 2595 stock on TipRanks’ Stock Analysis page.